Dr. Yee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Yawkey 9A
Boston, MA 02114Phone+1 617-724-4000
Summary
- Dr. Andrew J. Yee is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Massachusetts General Hospital and North Shore Medical Center. He is an Assistant Professor of Medicine at Harvard Medical School. He received his medical degree from Harvard Medical School and has been in practice 17 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2004 - 2007
Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
Harvard Medical SchoolClass of 2000
Certifications & Licensure
MA State Medical License 2002 - 2026
NH State Medical License 2009 - 2025- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2012 May 01
- Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) Start of enrollment: 2013 Mar 01
Publications & Presentations
PubMed
- Case 3-2025: A 54-Year-Old Man with Exertional Dyspnea and Chest Pain.Clyde W Yancy, J Sawalla Guseh 2nd, Brian G Ghoshhajra, Rodney H Falk, Andrew J Yee
The New England Journal of Medicine. 2025-01-23 - Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma.Johannes M Waldschmidt, Noori Sotudeh, Sankalp Arora, Tushara Vijaykumar, Praveen Anand
Blood Advances. 2025-01-15 - Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma.Rie Nakamoto-Matsubara, Valentina Nardi, Nora Horick, Tsuyoshi Fukushima, Ryan S Han
Blood Cancer Journal. 2024-12-23
Lectures
- Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Analysis of Hospitalization and Readmissions after CAR T Cell Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
